Show simple item record

dc.contributor.authorGómez Aguado, Itziar ORCID
dc.contributor.authorRodríguez Castejón, Julen ORCID
dc.contributor.authorVicente Pascual, Mónica
dc.contributor.authorRodríguez Gascón, Alicia
dc.contributor.authorSolinís Aspiazu, María Ángeles ORCID
dc.contributor.authorDel Pozo Rodríguez, Ana ORCID
dc.date.accessioned2020-03-03T17:17:00Z
dc.date.available2020-03-03T17:17:00Z
dc.date.issued2020-02-20
dc.identifier.citationNanomaterials 10(2) : (2020) // Article ID 364es_ES
dc.identifier.issn2079-4991
dc.identifier.urihttp://hdl.handle.net/10810/41920
dc.description.abstractThe use of messenger RNA (mRNA) in gene therapy is increasing in recent years, due to its unique features compared to plasmid DNA: Transient expression, no need to enter into the nucleus and no risk of insertional mutagenesis. Nevertheless, the clinical application of mRNA as a therapeutic tool is limited by its instability and ability to activate immune responses; hence, mRNA chemical modifications together with the design of suitable vehicles result essential. This manuscript includes a revision of the strategies employed to enhance in vitro transcribed (IVT) mRNA functionality and efficacy, including the optimization of its stability and translational efficiency, as well as the regulation of its immunostimulatory properties. An overview of the nanosystems designed to protect the mRNA and to overcome the intra and extracellular barriers for successful delivery is also included. Finally, the present and future applications of mRNA nanomedicines for immunization against infectious diseases and cancer, protein replacement, gene editing, and regenerative medicine are highlighted.es_ES
dc.description.sponsorshipThis research was funded by the MCIU/AEI/FEDER, UE (RTI2018-098672-B-I00), and by the UPV/EHU (GIU17/032).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/RTI2018-098672-B-I00es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectin vitro transcribed messenger RNA (IVT mRNA)es_ES
dc.subjectgene therapyes_ES
dc.subjectnanomedicinees_ES
dc.subjectimmunotherapyes_ES
dc.subjectinfectious disease vaccineses_ES
dc.subjectcancer immunotherapyes_ES
dc.subjectChimeric Antigen Receptor (CAR) T cellses_ES
dc.subjectdendritic cellses_ES
dc.subjectprotein replacementes_ES
dc.subjectgene editinges_ES
dc.titleNanomedicines to Deliver mRNA: State of the Art and Future Perspectiveses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2020-03-02T12:41:05Z
dc.rights.holder© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2079-4991/10/2/364/htmes_ES
dc.identifier.doi10.3390/nano10020364
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).